The Diagnostics Pillar is co-convened by FIND and the Global Fund, working closely with Unitaid, UNICEF, WHO and over 30 global health partners to scale-up equitable access to COVID-19 diagnostic technologies. 



Procuring over 150 million tests 

Halving the cost of COVID-19 rapid tests for low- and lower-middle income countries 

Ghana testing.jpeg


Assist the Diagnostics Consortium of 144 countries to reach a minimum testing rate of at least 1 per 1000 people per day

Purchase 988 million tests

Improve genetic sequencing capacity globally


In India, FIND partnered with the Institute of Genomics and Integrated Biology (CSIR-IGIB) to boost sequencing capacity across the country. The partnership aims to decentralize genomic surveillance of SARS-CoV-2, down to the district level, by setting up “MicroLabs” that enable sequencing, analysis and interpretation of sequencing data with minimal turnaround time in places with limited infrastructure. 

With the risk of a new variant of concern mounting by the day, the importance of point-of-care genome sequencing to track the evolution of the virus is also rising. The ACT-Accelerator has a track record of providing support to facilitate variant detection. It helped build the capacity to expand the use of next-generation sequencing for genomic surveillance in Southern Africa, which enabled the early detection of the Omicron variant.

In addition to helping detect variants, conducting genomic sequencing at a more local level also improves understanding of the mutations underlying vaccination breakthroughs, which can ultimately inform the development of new vaccines and identification of who might still be at high risk, even after vaccination.

Read more here

DIAGNOSTICS - MICROLABS PHOTO 2 - Sample processing at Inteermediate Reference Laboratory,


test tracker.png

Explore testing rates, changes over time, molecular vs rapid test data, and more.